Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group.

Fine RN, Kohaut EC, Brown D, Perlman AJ

The Journal of pediatrics1 Mar 1994Cited by 118 (Europe PMC)

PMID8120705DOI10.1016/s0022-3476(94)70358-2PepBankPUB-08120705

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with chronic renal failure, standardized height rose from -2.94 to -1.55 with rhGH versus -2.82 to -2.91 with placebo (p < 0.00005).
In plain wordsIn children with chronic renal failure, standardized height improved with rhGH compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseStandardized height
Study
n = 125
Comparator
Placebo
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Standardized height
−2.94 score
rhGH baseline
Standardized height
−1.55 score
rhGH 24 months
Standardized height
−2.82 score
placebo baseline
Standardized height
−2.91 score
placebo 24 months
Source sentences
Summary
Standardized height increased from -2.94 to -1.55 in the rhGH group after 24 months of treatment, and decreased from -2.82 to -2.91 in the placebo group (p < 0.00005).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070501
02HumanRandomized controlled trialEfficacy outcome
In children with chronic renal failure, creatinine clearance changes did not differ between rhGH and placebo after 24 months (p = 0.63).
In plain wordsIn children with chronic renal failure, kidney filtration changes did not differ significantly between rhGH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeCalculated creatinine clearance
Study
n = 125
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
There was no significant difference in the change in calculated creatinine clearance over baseline values in the rhGH group from that in the placebo group after 24 months of study (p = 0.63).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070506
03HumanRandomized controlled trialEfficacy outcome
In children with chronic renal failure, first-year growth was 10.7 +/- 3.1 cm/yr with rhGH versus 6.5 +/- 2.6 with placebo (p < 0.00005).
In plain wordsIn children with chronic renal failure, first-year growth was faster with rhGH than with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseFirst-year growth rate versus placebo
Study
n = 82
Comparator
Placebo
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · First yearAs given in this study (human).
Measurements
Growth rate
10.7 cm/yr
rhGH
Reported uncertainty
3.1 cm/yr
rhGH
Growth rate
6.5 cm/yr
placebo
Reported uncertainty
2.6 cm/yr
placebo
Source sentences
Summary
These growth rates were significantly greater than those in the placebo group (n = 27) in the first (6.5 +/- 2.6 cm/yr) and second (5.5 +/- 1.9 cm/yr) years (p < 0.00005 for both years).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients in the rhGH group who completed 24 months of study (n = 55) had a greater growth rate during the first year (10.7 +/- 3.1 cm/yr) than during the second year (7.8 +/- 2.1 cm/yr) of treatment.
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070503
04HumanRandomized controlled trialEfficacy outcome
In children with chronic renal failure, second-year growth was 7.8 +/- 2.1 cm/yr with rhGH versus 5.5 +/- 1.9 with placebo (p < 0.00005).
In plain wordsIn children with chronic renal failure, second-year growth was faster with rhGH than with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSecond-year growth rate versus placebo
Study
n = 82
Comparator
Placebo
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · Second yearAs given in this study (human).
Measurements
Growth rate
7.8 cm/yr
rhGH
Reported uncertainty
2.1 cm/yr
rhGH
Growth rate
5.5 cm/yr
placebo
Reported uncertainty
1.9 cm/yr
placebo
Source sentences
Summary
These growth rates were significantly greater than those in the placebo group (n = 27) in the first (6.5 +/- 2.6 cm/yr) and second (5.5 +/- 1.9 cm/yr) years (p < 0.00005 for both years).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients in the rhGH group who completed 24 months of study (n = 55) had a greater growth rate during the first year (10.7 +/- 3.1 cm/yr) than during the second year (7.8 +/- 2.1 cm/yr) of treatment.
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070504
05HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure completing rhGH treatment, growth was 10.7 +/- 3.1 cm/yr initially versus 7.8 +/- 2.1 cm/yr subsequently.
In plain wordsIn children with chronic renal failure receiving rhGH, growth was faster in the first treatment year than the second.
Peptide
HGH (somatotropin)
Outcome
IncreaseFirst-year versus second-year growth rate
Study
n = 55
Comparator
Second treatment year
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Growth rate
10.7 cm/yr
first year
Reported uncertainty
3.1 cm/yr
first year
Growth rate
7.8 cm/yr
second year
Reported uncertainty
2.1 cm/yr
second year
Source sentences
Summary
Patients in the rhGH group who completed 24 months of study (n = 55) had a greater growth rate during the first year (10.7 +/- 3.1 cm/yr) than during the second year (7.8 +/- 2.1 cm/yr) of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070502
06HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure receiving rhGH, mean change in height age exceeded mean change in bone age.
In plain wordsIn children with chronic renal failure receiving rhGH, height age increased more than bone age.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight age minus bone age change
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
The mean delta height age minus the delta bone age was positive in the rhGH group, suggesting improved final height potential.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070505
07HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure receiving rhGH, mean fasting insulin was elevated at 12 months.
In plain wordsIn children with chronic renal failure receiving rhGH, fasting insulin was elevated during treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFasting insulin at 12 months
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean fasting and postprandial insulin values were elevated at 12 months but not at 24 months in the rhGH-treated patients.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070507
08HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure receiving rhGH, mean postprandial insulin was elevated at 12 months.
In plain wordsIn children with chronic renal failure receiving rhGH, insulin after meals was elevated during treatment.
Peptide
HGH (somatotropin)
Outcome
IncreasePostprandial insulin at 12 months
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Mean fasting and postprandial insulin values were elevated at 12 months but not at 24 months in the rhGH-treated patients.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070508
09HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure receiving rhGH, mean fasting insulin was not elevated at 24 months.
In plain wordsIn children with chronic renal failure receiving rhGH, fasting insulin was not elevated after longer treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeFasting insulin at 24 months
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Mean fasting and postprandial insulin values were elevated at 12 months but not at 24 months in the rhGH-treated patients.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070509
10HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure receiving rhGH, mean postprandial insulin was not elevated at 24 months.
In plain wordsIn children with chronic renal failure receiving rhGH, insulin after meals was not elevated after longer treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changePostprandial insulin at 24 months
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Mean fasting and postprandial insulin values were elevated at 12 months but not at 24 months in the rhGH-treated patients.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070510
11HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure receiving rhGH, fasting glucose was not significantly elevated over baseline at 24 months.
In plain wordsIn children with chronic renal failure receiving rhGH, fasting glucose did not increase significantly from baseline.
Peptide
HGH (somatotropin)
Outcome
No significant changeFasting glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Mean fasting and 2-hour postprandial glucose values at 24 months were not significantly elevated over baseline values in either group.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070511
12HumanNon-randomized trialEfficacy outcome
In children with chronic renal failure receiving rhGH, postprandial glucose was not significantly elevated over baseline at 24 months.
In plain wordsIn children with chronic renal failure receiving rhGH, glucose after meals did not increase significantly from baseline.
Peptide
HGH (somatotropin)
Outcome
No significant changePostprandial glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Mean fasting and 2-hour postprandial glucose values at 24 months were not significantly elevated over baseline values in either group.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred twenty-five prepubertal growth-retarded children with chronic renal failure were randomly assigned to receive either rhGH (n = 82) or placebo (n = 43) for 2 years.
Report a problemFND-0812070512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.